Furthermore, in vitro experiments have confirmed that paclitaxel reprogrammes M2 polarized macrophages into M1-like phenotypes in a TLR4-dependent manner, promoting the effectiveness of anti-tumor immunotherapy (Wanderley et al., 2018). This evidence concerns the gene TLR4 and neoplasm.